[ICU acquired neuromyopathy].

G. Gueret (1) , Maïté Guillouët (1) , V. Vermeersch (1) , E. Guillard (2) , Hélène Talarmin (2) , B.-V. Nguyen , François Rannou (1) , M.-A. Giroux-Metges (1) , J.-P. Pennec (1) , Y. Ozier (3)

1 MUST
2 M2S - Laboratoire Mouvement Sport Santé
3 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale

ICU acquired neuromyopathy (IANM) is the most frequent neurological pathology observed in ICU. Nerve and muscle defects are merged with neuromuscular junction abnormalities. Its physiopathology is complex. The aim is probably the redistribution of nutriments and metabolism towards defense against sepsis. The main risk factors are sepsis, its severity and its duration of evolution. IANM is usually diagnosed in view of difficulties in weaning from mechanical ventilation, but electrophysiology may allow an earlier diagnosis. There is no curative therapy, but early treatment of sepsis, glycemic control as well as early physiotherapy may decrease its incidence. The outcomes of IANM are an increase in morbi-mortality and possibly long-lasting neuromuscular abnormalities as far as tetraplegia.

Domaines: Physiologie [q-bio.TO]

G. Gueret, Maïté Guillouët, V. Vermeersch, E. Guillard, Hélène Talarmin, et al.. [ICU acquired neuromyopathy].. Annales Françaises d'Anesthésie et de Réanimation, 2013, 32 (9), pp.580-91. ⟨10.1016/j.annfar.2013.05.011⟩. ⟨hal-00881574⟩